Gradient Investments’s Emergent Biosolutions EBS Stock Holding History

Gradient Investments’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-29	Closed	-$2K	–	1125
2019 Q3	$2K	Buy	+29	New	+$1.35K	﹤0.01%	918

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gradient Investments's EBS Position: Q4 2019 in Review

Gradient Investments sold out of Emergent Biosolutions (EBS) in Q4 2019, closing a stake of 29 shares — an estimated $2K sold.

Gradient Investments first reported a position in EBS in Q3 2019 and held it in 1 quarter. The position peaked at $2K in Q3 2019. 236 funds tracked by Wall St. Rank hold EBS as of Q4 2019.

Gradient Investments reported no remaining Emergent Biosolutions position as of Q4 2019 after selling out during the quarter.
Gradient Investments sold 29 Emergent Biosolutions shares in Q4 2019, an estimated $2K.
Gradient Investments first reported a position in Emergent Biosolutions in Q3 2019 and held it in 1 quarter.
Gradient Investments's Emergent Biosolutions position peaked at $2K in Q3 2019.
236 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2019.

Based on Gradient Investments's 13F filing for Q4 2019, filed 15 Jan 2020.